Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTX-007
- Development stage
- Preclinical
- Lead developer
- Leal Therapeutics
- Modality
- Small Molecules
01
Overview
LTX-007 is a small molecule inhibitor of serine palmitoyltransferase (SPT) developed by Leal Therapeutics. It is designed to modulate sphingolipid metabolism by inhibiting SPT, the rate-limiting enzyme in the de novo synthesis of sphingolipids. This inhibition aims to reduce the accumulation of excessive ceramides and other sphingolipids in the central nervous system (CNS), which is implicated in the pathogenesis of various neurodegenerative and metabolic disorders. LTX-007 is currently in preclinical development for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), rare sphingolipidoses, and obesity.
02
Targets
SPT (Serine palmitoyltransferase)
Beyond the preview
Go deeper on LTX-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTX-007.